Press Releases

Date Title and Summary View
August 14, 2017 Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results
-- Announced Data and Safety Monitoring Board Recommendation to Continue Phase 3 Registration Trial of Vicinium™ as Planned -- -- Entered Collaboration with National Cancer Institute and AstraZeneca to Evaluate Vicinium in Combination with Imfinzi™ (Durvalumab) in Patients with Non-Muscle Invasive
View HTML
August 7, 2017 Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017 View HTML
August 3, 2017 Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference View HTML
June 12, 2017 Eleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference View HTML
June 6, 2017 Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer View HTML
June 1, 2017 Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data View HTML
May 17, 2017 Eleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development View HTML
May 4, 2017 Eleven Biotherapeutics Reports First Quarter 2017 Financial Results View HTML
April 28, 2017 Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017 View HTML
April 2, 2017 Eleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company's Locally- and Systematically-Administered Drug Candidates View HTML